ASBP logo

ASPIRE-LAKEWOOD HOLDINGS INC

ASBPNASDAQ
πŸ† #5436 by market capUS Equity
$8.50β–² $0.00 (+0.00%)
Live
πŸ””
Track ASBP
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.0%
7dβ–² 4.8%
14dβ–² 5.2%
30dβ–Ό 0.8%
ytdβ–Ό 94.6%
1yβ–Ό 97.7%
🏦Market Cap
$980,662
Small Cap
πŸ“ˆRevenue Growth (YoY)
+0.0%
Slowing
πŸ“ŠGross Margin
18.4%
Thin
πŸ’΅FCF Margin
-7358.2%
Thin
βš–οΈP/S Ratio
10.0x
Elevated
Otter Score
64
Fair

Trading Snapshot

Day Range
$8.39 – $8.64
52-Week Range
$0.11 – $562.80
Volume
$3.04B
Avg Volume
$2.36B
Shares Outstanding
115,372
Next Earnings
Nov 15, 2026

Fundamentals Snapshot

Annual Revenue
$6,202
Last Q Revenue
$63,103
P/E Ratio
-1.1
P/S Ratio
10.0x
EPS (TTM)
$-10.65
Dividend Yield
0.00%
Dilution (1yr)
+6399.8%

Why Investors Own ASBP

  • βœ“High-growth profile β€” revenue up +42.8% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 27% gross margin and 23% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ASBP logo

ASPIRE-LAKEWOOD HOLDINGS INC

ASBP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6Kβ–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$19Mβ–² +1498.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–² +1756.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.5Mβ–² +6399.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$4Mβ–Ό βˆ’$3M YoY
StockOtter Β· stockotter.space

About ASPIRE-LAKEWOOD HOLDINGS INC

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Price Target

β“˜
Average Target
$11.31
β–² +33.0% Upside
High Target$13.37
Low Target$10.58
Based on 17 analysts

Latest News & Updates

AccesswireΒ·20d ago

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

Brings total authorized repurchase to $10 million Reflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunity Increased authorization su

AccesswireΒ·21d ago

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

ESTERO, FL / ACCESS Newswire / September 8, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "Aspire Biopharma Holdings, Inc."

AccesswireΒ·Aug 13

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at S

AccesswireΒ·Aug 10

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets

Defense WorldΒ·Aug 4

Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9% – Time to Buy?

Shares of Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP - Get Free Report) rose 10.9% on Monday. The stock traded as high as $7.44 and last traded at $7.23. 27,396 shares changed hands during trading, a decline of 49% fr

AccesswireΒ·Jul 20

Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)

High-Octane Partnership: Multi-time X Games medalist Jarryd McNeil joins BUZZ BOMBβ„’ to fuel brand expansion in action sports. Consumer Connection: The collaboration strengthens BUZZ BOMBβ„’'s commitment to delivering fast-